In the neoadjuvant setting, the addition of pembrolizumab to an anthracycline and taxane-containing chemotherapy backbone resulted in an increased pCR rate in patients with HR-positive/HER2-negative breast cancer in the I-SPY2 clinical trial (21). The gene discussed is ERBB2; the disease is breast carcinoma.